Vetvicka V, Vetvickova J, Hilgert I, Voburka Z, Fusek M
Department of Pathology, School of Medicine, University of Louisville, KY 40292, USA.
Int J Cancer. 1997 Nov 4;73(3):403-9. doi: 10.1002/(sici)1097-0215(19971104)73:3<403::aid-ijc15>3.0.co;2-d.
Cathepsin D, a lysosomal aspartic proteinase, is secreted in the form of enzymatically inactive proenzyme by many types of human breast cancer tissue and exerts mitogenic activity toward these tissues. Flow cytometry was used to test the binding of procathepsin D purified from the secretion of the breast cancer cell line ZR-75-1 to human breast cancer cells. No previously known surface antigens or soluble M6P-R or anti-M6P-R antibodies were found to inhibit the specific binding of procathepsin D-FITC. Similarly, none of these potential inhibitors was found to inhibit growth factor activity of procathepsin D. Our results indicate that procathepsin D growth factor activity is mediated by a new, previously unknown receptor moiety and that the binding activity can be localized in position 27-44 of the activation peptide of procathepsin D. Furthermore, in vivo experiments indicate that treatment with anti-procathepsin D antibodies can reverse the growth of human breast tumors in athymic nude mice.
组织蛋白酶D是一种溶酶体天冬氨酸蛋白酶,多种人类乳腺癌组织会以无酶活性的酶原形式分泌该物质,且其对这些组织具有促有丝分裂活性。采用流式细胞术检测从乳腺癌细胞系ZR-75-1分泌物中纯化的组织蛋白酶D酶原与人乳腺癌细胞的结合情况。未发现任何已知的表面抗原、可溶性M6P-R或抗M6P-R抗体可抑制组织蛋白酶D-FITC的特异性结合。同样,未发现这些潜在抑制剂中的任何一种可抑制组织蛋白酶D的生长因子活性。我们的结果表明,组织蛋白酶D酶原的生长因子活性由一种新的、此前未知的受体部分介导,且结合活性可定位于组织蛋白酶D酶原激活肽的第27-44位。此外,体内实验表明,用抗组织蛋白酶D抗体治疗可逆转无胸腺裸鼠体内人乳腺肿瘤的生长。